Medicamen Biotech: SEBI Takeover Disclosure Filed

M&A / JV 22 Jun 2026 · Filed / open· ✓ Verified

Under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulation 31(4) requires disclosure to the exchange when a substantial acquisition threshold is crossed or a takeover offer is contemplated. This filing indicates Medicamen Biotech is subject to such a transaction. The full disclosure document, held in the NSE archives, would contain details of the acquirer, shareholding pattern, consideration and regulatory approvals required.

Why it mattersMandatory Regulation 31(4) disclosure triggers strict timing and transparency obligations; the target must await regulator clearance and completion conditions before announcing material details.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals